Icahn School of Medicine at Mount Sinai
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Icahn School of Medicine at Mount Sinai sits in the top decile of US sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count).
Icahn School of Medicine at Mount Sinai: 708 sponsored US clinical trials, 163 recruiting.
Icahn School of Medicine at Mount Sinai sponsors 708 registered US clinical trials on ClinicalTrials.gov, 163 of them currently recruiting, and 423 completed. 88 of these trials are in Phase 3-4 (later-stage) and 138 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 7 trials.
Top-decile sponsor footprint
Icahn School of Medicine at Mount Sinai ranks in the top decile of sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
423 of 499 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
708 total, page 11 of 15
Vitamin D3 in Patients With Sickle Cell Disease
NCT03012555
Monitoring of Vital Signs During Skin-to-skin Holding by Mothers of Their Preterm Babies
NCT02231801
Cognitive Training for Mood and Anxiety Disorders
NCT02256566
Comparison of Nutrition Education Alone or With Acupuncture for Weight Loss in Breast Cancer Patients Post-Chemotherapy
NCT02081612
Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT02569437
Improving Medication-taking After Liver Transplant
NCT01960322
Study to Treat Major Depressive Disorder (MDD) With a New Medication
NCT02149836
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
NCT02247037
Reversing Ticagrelor's Effects With Fresh Platelets
NCT02201394
World Trade Center (WTC) RENAL
NCT02246101
Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles
NCT02181790
Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
NCT02132767
Intrathecal Hydromorphone for Pain Control After Cesarean Section
NCT02096003
Reduction of Pain Caused by Biologic Drugs in Psoriasis
NCT02168244
Post Excision/Mohs Scar Laser Resurfacing
NCT02130297
A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder
NCT01970345
A Yoga Program for Breast Cancer Patients Undergoing Chemotherapy
NCT02360904
Observational Study to Evaluate Ventral Incisional Hernia Repair Using a Biologic Mesh (Cook Biodesign)
NCT02129140
Neuromyelitis Optica (NMO) & Cetirizine
NCT02865018
Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
NCT02107261
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
NCT02072148
Treatment With Nab-paclitaxel in Cutaneous SCC
NCT02076243
Mindfulness Meditation for Spine Surgery Pain
NCT02104349
Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease
NCT02054533
Latino Peers as Patient Navigators for Colon Cancer Screening
NCT02226107
CRT-Guanfacine for SPD
NCT02524899
Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil
NCT01965925
Early Protein Supplementation of Human Milk in Extremely Low Birth Weight Infants
NCT01991613
Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection
NCT02294136
Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease
NCT02142101
Monitoring With Ultrasound Imaging of Intrauterine Device (IUD) Position Placed Immediately After Giving Birth
NCT02024672
Manuka Honey for Wound Care
NCT02259491
Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
NCT01990560
Riluzole in Mild Alzheimer's Disease
NCT01703117
Healthy Body Study
NCT02011646
Observational Analysis of the Cause of Leaks When Bowel is Cut and Reconnected
NCT02178228
An Educational Intervention for Patients With Bladder Cancer
NCT01915121
Rosuvastatin and Evolocumab for Coronary Artery Disease
NCT05984953
Cognitive Training for Depression II
NCT01934491
Motivational Interviewing for Colonoscopy
NCT01877096
Handheld Ultrasound Evaluation of the Inferior Vena Cava to Guide Heart Failure Treatment
NCT01962688
Ketamine Plus Lithium in Treatment-Resistant Depression
NCT01880593
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
NCT01837823
Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
NCT01871545
Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream
NCT02153762
Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
NCT02251652
Women's INternational Transcatheter Aortic Valve Implantation Registry
NCT01819181
Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp
NCT01836367
Smartphone Technology and CBT-GSH in Binge Eaters
NCT02399982
CAUSE Trial: Patient Specific-Cellular Characterization of Fibromuscular Dysplasia and High-Risk Atherosclerotic Endothelium
NCT01808729
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 81 |
| Phase 3 | 21 |
| Phase 4 | 67 |
Therapeutic Areas
What is open in the Icahn School of Medicine at Mount Sinai pipeline
163 recruiting of 708 indexed (23% open); 423 completed (60%).
Phase mix: 88 late (III/IV) vs 138 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Icahn School of Medicine at Mount Sinai: open-pipeline peers nationwide
Peers matched on 708 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 708 trials (± recruiting share)
- Sanofi · 713 trials · 10% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
- University of Miami · 721 trials · 20% recruiting
- The Cleveland Clinic · 688 trials · 14% recruiting
Sponsors near 23% open enrollment (± trial volume)
- Clemson University · 23% recruiting · 13 trials
- Liberating Technologies · 23% recruiting · 13 trials
- Rahul Aggarwal · 23% recruiting · 13 trials
- Sequenom · 23% recruiting · 26 trials
Related
What to do with this Icahn School of Medicine at Mount Sinai page
708 registered trials is a research-attention snapshot, not an endorsement of Icahn School of Medicine at Mount Sinai or any single study.
- 163 of Icahn School of Medicine at Mount Sinai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Icahn School of Medicine at Mount Sinai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Icahn School of Medicine at Mount Sinai pipeline card: 708 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.